Related Experiment Video
Updated: Jul 5, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Clinical analysis of multiple primary malignancies in the elderly
Andrea Luciani1, G Ascione, D Marussi
1Medical Oncology Unit, S. Paolo Hospital, Via DI Rudinì 8, 20142 Milan, Italy. andrea_luciani@email.it
Medical Oncology (Northwood, London, England)
|May 17, 2008
Summary
Elderly patients have a higher incidence of multiple primary malignancies (MPM) than younger individuals. Smoking-related cancers, like lung and head and neck, show a significant association in MPM cases.
Area of Science:
- Oncology
- Geriatrics
- Epidemiology
Background:
- Cancer incidence increases with age, with a projected rise in neoplasms among individuals over 65.
- The aging global population is expected to lead to a higher prevalence of multiple primary malignancies (MPM).
Purpose of the Study:
- To compare the prevalence of MPM in elderly versus younger cancer patients.
- To identify patterns and associations of MPM in different age groups.
Main Methods:
- Retrospective review of 1,503 cancer patients (January 2004 - January 2007).
- Definition of MPM by Warren and Gates.
- Statistical analysis including t-test and Mc Nemar test, with age stratification.
Main Results:
- MPM prevalence was 15% in elderly (≥70 years) versus 6% in younger patients (P=0.001).
- In elderly males, MPM prevalence was 21% compared to 14% in females.
- Common MPM associations included prostate with lung (11%) and prostate with colorectal cancer (11%). Smoking-related cancers (lung, head and neck) also showed association.
Conclusions:
- Elderly patients exhibit a significantly higher likelihood of developing MPM.
- Smoking-related cancers demonstrate a significant association within MPM, supporting the field cancerogenesis concept.
- Other MPM occurrences appeared to be random, without clear etiological links.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...